| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nextgen Biomed Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪1.12 |
| 52 Week High | ₪3.72 |
| 52 Week Low | ₪0.95 |
| Beta | 0.86 |
| 1 Month Change | 6.08% |
| 3 Month Change | -14.86% |
| 1 Year Change | -68.66% |
| 3 Year Change | -94.94% |
| 5 Year Change | -56.91% |
| Change since IPO | -97.67% |
Recent News & Updates
Shareholder Returns
| NXGN | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | -5.8% | -3.6% | -3.1% |
| 1Y | -68.7% | -14.2% | 9.5% |
Return vs Industry: NXGN underperformed the IL Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: NXGN underperformed the IL Market which returned 10% over the past year.
Price Volatility
| NXGN volatility | |
|---|---|
| NXGN Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.0% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: NXGN's share price has been volatile over the past 3 months.
Volatility Over Time: NXGN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 15 | Harel Hershtik | www.nextgen-biomed.com |
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group Com Ltd.
Nextgen Biomed Ltd Fundamentals Summary
| NXGN fundamental statistics | |
|---|---|
| Market cap | ₪8.07m |
| Earnings (TTM) | -₪9.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs NXGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXGN income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪9.00m |
| Earnings | -₪9.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NXGN perform over the long term?
See historical performance and comparison